5/2/2006 | BT | Market Commentary: Vical top pick in bird flu flock; Noven sinks on profit taking; NitroMed dives, Myriad higher
|
2/10/2006 | BT | Market Commentary: Acorda shares close up 12%; Shire better, other ADHD names off on drug labeling; Pfizer slides
|
2/10/2006 | BT | Shire: Additional studies of Adderall better than 'black box' warning on cardiovascular risks
|
2/3/2006 | BT | Shire files for European approvals of SPD476 for colitis
|
1/23/2006 | BT | Shire says it disagrees with agency's decision not to allow drugs for mild Alzheimer's disease patients
|
1/20/2006 | BT | Market Commentary: DOR BioPharma stock jumps 15.6% on orBec news, equity line; Shire, Impax settle patent suit
|
1/19/2006 | BT | Shire, Impax settle pending Adderall litigation, sign agreement for Carbatrol
|
1/18/2006 | BT | Shire fights to keep Adderall XR patent
|
11/14/2005 | BT | Shire says Fosrenol study shows long-term efficacy, safety for end-stage renal disease patients
|
11/11/2005 | BT | Impax files complaint against Shire, saying Adderall XR patent invalid, not infringed
|
11/1/2005 | BT | Shire's SPD476 leads to remission in ulcerative colitis patients, studies show
|
10/28/2005 | BT | Shire says Adderall XR can benefit adults with ADHD
|
10/28/2005 | BT | Shire: Trial results positive for idursulfase to treat rare Hunter syndrome
|
10/27/2005 | BT | Shire methylphenidate patch scheduled for FDA committee review
|
10/24/2005 | BT | Impax says Shire affiliate files complaint for third Adderall XR patent
|
10/20/2005 | BT | Shire files Adderall patent suit against Barr, Impax Laboratories
|
9/8/2005 | BT | Shire plans to create holding company to allow dividend payments
|
9/6/2005 | BT | Market Commentary: Chiron rises on rejection of bid from Novartis; Barr, Teva gain; New River higher; Andrx falls
|
8/24/2005 | BT | Market Commentary: Shire rises on Adderall news; New River retraces gain; Barr declines; Genaera gains; Oscient Pharma off
|
7/12/2005 | BT | Market Commentary: Planet Biotech targets VC funds; Rigel, Keryx decline; Genentech rises, pushes OSI Pharma higher
|
7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
6/29/2005 | BT | Market Commentary: CV Therapeutics, Lonza upsize convertibles, both higher in trade; Millennium gains on new CEO
|
6/29/2005 | CV | Market Commentary: CV Therapeutics' new deal gains, supporting biotechs; Mirant trades in heavy volume; General Mills eases
|
8/23/2004 | CV | Shire Pharmaceuticals says holders of $366.2 million of 2% convertibles exercise put
|
1/10/2003 | CV | Merrill removes Shire convert as a yield alternative in its model portfolio
|
1/9/2003 | CV | Market Commentary: Cendant gets boost from straight bond deal, Tyco putable issues gain sharply
|